@article{oai:kanazawa-u.repo.nii.ac.jp:00055461,
 author = {藤村, 隆 and 太田, 哲生 and 尾山, 勝信 and 宮下, 知治 and 三輪, 晃一 and Fujimura, Takashi and Ohta, Tetsuo and Oyama, Katsunobu and Miyashita, Tomoharu and Miwa, Koichi},
 issue = {9},
 journal = {World Journal of Gastroenterology},
 month = {},
 note = {Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However, coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP), which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum, and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors. © 2006 The WJG Press. All rights reserved., 金沢大学医薬保健研究域医学系},
 pages = {1336--1345},
 title = {Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience},
 volume = {12},
 year = {2006}
}